Back to News
Market Impact: 0.6

Consortium led by Nordic Capital, Permira to acquire Bavarian Nordic

M&A & RestructuringHealthcare & BiotechCompany FundamentalsPrivate Markets & VentureMarket Technicals & FlowsInvestor Sentiment & Positioning
Consortium led by Nordic Capital, Permira to acquire Bavarian Nordic

A consortium led by Nordic Capital and Permira has agreed to acquire vaccine maker Bavarian Nordic for 233 Danish crowns per share in an all-cash offer, valuing the company at approximately 19 billion crowns ($2.98 billion). This represents a 21% premium over Bavarian Nordic's closing price last Wednesday, and the company has recommended investors accept the bid. The deal, which follows a 24% surge in Bavarian Nordic's shares on news of potential talks, is contingent on the consortium securing over 90% of shares and voting rights, after which Bavarian Nordic will be delisted from Nasdaq Copenhagen.

Analysis

A consortium, led by private equity firms Nordic Capital and Permira, has made a definitive all-cash offer to acquire vaccine manufacturer Bavarian Nordic for 233 Danish crowns per share. This bid values the company's equity at approximately 19 billion DKK ($2.98 billion) and represents a significant 21% premium over its closing price of 192.50 DKK last Wednesday. The market had already anticipated a potential transaction, with the stock jumping as much as 24% on Thursday following confirmation of talks. Bavarian Nordic's board has formally recommended that shareholders accept the offer, a key endorsement that increases the probability of the deal's success. The transaction is contingent upon the acquirer, Innosera, securing acceptances for over 90% of Bavarian Nordic's shares and voting rights. Upon completion, the acquirer intends to delist the company from Nasdaq Copenhagen, transitioning it to private ownership.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo